More Information »Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that was first identified in anaplastic large cell lymphoma (ALCL) as part of the fusion protein NPM-ALK. ALK has been implicated in the pathogenesis of many types of cancer.
Product Name / Activity
|Potent anaplastic lymphoma kinase (ALK) inhibitor; also potent ACK inhibitor|
|Potent c-MET/ALK inhibitor|
|Potent ALK inhibitor; also IR and IGF1R inhibitor|
|Potent Ack1 and ALK dual inhibitor; orally bioavailable|
|High affinity and selective ALK and ROS1 inhibitor|